Published in:
10-05-2023 | Supraventricular Tachycardia | Commentary
Adenosine Administration in Supraventricular Tachycardia: Single- or Double-Syringe Technique?
Authors:
Marco Zuin, Gianluca Rigatelli
Published in:
American Journal of Cardiovascular Drugs
|
Issue 4/2023
Login to get access
Excerpt
The term supraventricular tachycardia (SVT) indicates a heterogeneous group of arrhythmias generated by cardiac tissue at the His bundle or above [
1]. A larger body of evidence has already demonstrated that SVT represents a common cause of hospitalization worldwide which increases both patient morbidity and mortality [
2,
3]. In daily clinical practice, the most common forms of SVT are represented by atrioventricular nodal re-entrant tachycardia, atrioventricular re-entrant tachycardia and atrial tachycardia [
4]. From an epidemiological perspective, previous analyses have estimated an SVT prevalence of about 2.25 per 1000 persons, with a female predominance of 2:1 [
5]. Generally, we can identify two distinct subsets of patients with SVT: those with other concomitant cardiovascular disease and those with lone SVT [
6]. …